Truist Financial Analysts Boost Earnings Estimates for Scientific Games Co. (NASDAQ:SGMS)

Truist Financial Analysts Boost Earnings Estimates for Scientific Games Co. (NASDAQ:SGMS)

Scientific Online games Co. (NASDAQ:SGMS – Get Rating) – Truist Monetary upped their Q4 2022 earnings for each share (EPS) estimates for Scientific Games in a research report issued on Tuesday, March 1st. Truist Fiscal analyst B. Jonas now expects that the engineering company will make $.38 for each share for the quarter, up from their preceding forecast of $.29. Truist Financial at the moment has a “Invest in” rating and a $85.00 concentrate on price on the inventory.

SGMS has been the matter of a quantity of other studies. Credit rating Suisse Group boosted their target price on shares of Scientific Online games from $45.00 to $52.00 and gave the inventory an “underperform” score in a report on Thursday. StockNews.com downgraded shares of Scientific Online games from a “invest in” ranking to a “hold” ranking in a report on Wednesday, February 23rd. Lastly, Deutsche Bank Aktiengesellschaft reduced their goal rate on shares of Scientific Video games from $71.00 to $67.00 and set a “keep” score on the stock in a report on Wednesday. One analyst has rated the stock with a promote rating, 4 have assigned a maintain ranking and 4 have issued a buy ranking to the organization. In accordance to data from MarketBeat, the stock has a consensus score of “Keep” and a consensus focus on value of $81.44.

Shares of SGMS opened at $63.57 on Friday. The firm’s 50 working day going regular price is $61.70 and its two-hundred working day moving normal cost is $69.31. The business has a current market cap of $6.14 billion, a P/E ratio of 34.74 and a beta of 1.95. Scientific Video games has a twelve month small of $36.89 and a twelve month significant of $90.20. Scientific Video games (NASDAQ:SGMS – Get Score) last issued its quarterly earnings knowledge on Tuesday, March 1st. The technology corporation claimed $.95 earnings for every share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($.36) by $1.31. Scientific Games had a internet margin of 6.39{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} and a damaging return on fairness of 5.54{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. The company had earnings of $580.00 million in the course of the quarter, as opposed to analysts’ anticipations of $558.79 million. All through the exact quarter in the previous year, the company earned ($.59) earnings for each share. The business’s revenue for the quarter was up 20.8{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} on a 12 months-in excess of-yr foundation.

(Advertisement)

Hey, Tim Sykes here… and if you never know how to spot these vintage investing patterns… then grab my no cost E book correct now… Plus, I’ll share my #1 rule for investing Penny Shares.

Many hedge resources have lately additional to or lowered their stakes in SGMS. FORA Capital LLC acquired a new situation in shares of Scientific Games in the 2nd quarter valued at about $46,000. US Bancorp DE lifted its position in Scientific Video games by 121.5{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} for the duration of the third quarter. US Bancorp DE now owns 866 shares of the technological know-how company’s inventory really worth $71,000 right after buying an further 475 shares in the course of the time period. Dim Forest Funds Administration LP bought a new stake in Scientific Online games all through the third quarter value about $108,000. Convergence Investment decision Partners LLC purchased a new stake in Scientific Game titles all through the third quarter truly worth about $169,000. Last but not least, Keebeck Alpha LP purchased a new stake in Scientific Game titles through the 3rd quarter value about $207,000. Institutional traders and hedge cash own 93.19{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the company’s stock.

About Scientific Game titles (Get Ranking)

Scientific Online games Corp. engages in the improvement of engineering-based merchandise and products and services and associated articles. It operates by means of the adhering to enterprise segments: Gaming, Lottery, SciPlay, and Electronic. The Gaming section models, develops, manufactures, markets, and distributes a comprehensive portfolio of gaming solutions and solutions.

Showcased Content articles

Earnings History and Estimates for Scientific Games (NASDAQ:SGMS)

This immediate information alert was produced by narrative science technology and money data from MarketBeat in get to present readers with the speediest and most correct reporting. This tale was reviewed by MarketBeat’s editorial crew prior to publication. Please mail any concerns or responses about this story to [email protected]

Really should you invest $1,000 in Scientific Online games right now?

In advance of you take into account Scientific Video games, you will want to hear this.

MarketBeat keeps observe of Wall Street’s best-rated and ideal undertaking research analysts and the stocks they advise to their clientele on a day by day foundation. MarketBeat has determined the five stocks that leading analysts are quietly whispering to their purchasers to buy now ahead of the broader market catches on… and Scientific Video games was not on the listing.

While Scientific Game titles now has a “Hold” rating among the analysts, leading-rated analysts believe that these 5 shares are much better buys.

Check out The 5 Shares Below

 

Capital One Financial, Thermo Fisher Scientific, Aflac, DexCom and Exxon Mobil

For Immediate Release

Chicago, IL – October 27, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Capital One Financial Corp. COF, Thermo Fisher Scientific Inc. TMO, Aflac Inc. AFL, DexCom Inc. DXCM and Exxon Mobil Corp. XOM.

Here are highlights from Tuesday’s Analyst Blog:

5 S&P 500 Stocks to Buy Ahead of Q3 Earnings This Week

We are in the first major week of the third-quarter 2021 earnings season with more than 900 companies slated to release their quarterly results. While market participants’ attention will be predominantly on technology giants, several other companies from the S&P 500 stable will also release their financial numbers.

The last quarter was a mixed one for the S&P 500 Index as the benchmark gained a marginal 0.2{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. Good performances in July and August were almost offset in September’s market turmoil. Investment in S&P 500 companies with a favorable Zacks Rank that are set to beat earnings estimates should be fruitful going forward.

Robust Start to Third-Quarter Earnings

The third-quarter 2021 earnings season has picked up from where it ended in the second quarter.  Results are pretty encouraging so far despite prolonged supply-chain disruptions, a labor shortage, higher inflationary pressure and the resurgence of the Delta variant of the coronavirus.

As of Oct 22, 117 S&P 500 companies reported third-quarter results. Total earnings of these companies are up 46.2{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} year over year on 16.3{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} higher revenues with 85.5{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} beating EPS estimates and 73.5{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} surpassing revenue estimates.

At present, total third-quarter earnings of the market’s benchmark — the S&P 500 Index — are projected to jump 32.5{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} from the same period last year on 14.4{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} higher revenues. This suggests a steady improvement from 26.1{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} earnings growth on 14{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} higher revenues, estimated at the beginning of the reporting cycle.  

Favorable Impacts on Earnings Results

Earnings results of the first two quarters of this year were favorably impacted since the corresponding quarters of last year were affected by the pandemic-led lockdowns and restrictions. This was evident with 95{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} year-over-year earnings growth on 25.3{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} higher revenues in the second quarter and 49.3{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} year-over-year earnings growth on 10.3{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} higher revenues in first-quarter 2021.

Nevertheless, the U.S. economy started reopening partially albeit at a languid pace since the third quarter of 2020. Notwithstanding favorable comparisons with last year, third-quarter 2021 earnings estimates reflect genuine growth, climbing nearly 23{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} from the pre-pandemic third-quarter of 2019.

Our Top Picks

Five big S&P 500 companies (market capital > $45 billion) are slated to release third-quarter earnings results this week. Each of these stocks carries either a Zacks Rank#1 (Strong Buy) or 2 (Buy) and has a positive Earnings ESP. You can see the complete list of today’s Zacks #1 Rank stocks here.

Our research shows that for stocks with the combination of a Zacks Rank #3 (Hold) or better and a positive Earnings ESP, the chance of an earnings beat is as high as 70{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. These stocks are anticipated to appreciate after earnings releases. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Capital One Financial is primarily focused on consumer and commercial lending as well as deposit origination providing various financial products and services in the United States, the United Kingdom, and Canada. It operates through three segments: Credit Card, Consumer Banking and Commercial Banking.

The company’s Credit Card segment is likely to continue showing strength. In the first half of 2021, Domestic Card, which accounted for 92.2{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the Credit Card net revenues, reflected robust loans held for investment balance.

This Zacks Rank #2 company has an Earnings ESP of +4.66{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. It has an expected earnings growth rate of more than 100{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} for the current year. The Zacks Consensus Estimate for current-year earnings improved 1.3{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} over the last 30 days. It recorded earnings surprises in the last four reported quarters, with an average beat of 92.3{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. The company is set to release earnings results on Oct 26, after the closing bell.

Thermo Fisher Scientific delivered a strong performance in the first half of 2021 banking on accelerated growth in Base business. Solid end-market growth was driven by robust fundamentals in the life sciences, strong economic activity globally and the role this industry is playing in the pandemic response.

Thermo Fisher is currently expanding its bioproduction purification resin capacity, which is used in the mRNA manufacturing process. In Biosciences business, it launched several new products, including two instruments to advance cell analysis- the Invitrogen Bigfoot Spectral Sorter and the Invitrogen Attune CytPix Flow Cytometer.

This Zacks Rank #2 company has an Earnings ESP of +3.02{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. It has an expected earnings growth rate of 13.2{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} for the current year. The Zacks Consensus Estimate for current-year earnings improved 0.2{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} over the last 7 days. It recorded earnings surprises in the last four reported quarters, with an average beat of 10.4{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. The company is set to release earnings results on Oct 27, before the opening bell.

Aflac continues to maintain strong risk-adjusted capital at its operating subsidiaries supported by consistent earnings and good liquidity. Its U.S segment is poised to grow from the buyout of Argus Dental and Vision and Zurich North America’s U.S. Corporate Life and Pensions (Group Benefits) business. A robust product pipeline for 2021 is likely to boost the segment’s sales.

This Zacks Rank #2 company has an Earnings ESP of +1.44{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. It has an expected earnings growth rate of 13.1{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} for the current year. The Zacks Consensus Estimate for current-year earnings improved 0.2{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} over the last 30 days. It recorded earnings surprises in the last four reported quarters, with an average beat of 19.9{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. The company is set to release earnings results on Oct 27, after the closing bell.

DexCom made continued advancements with respect to key strategic objectives. DexCom’s slew of tie-ups and buyouts are also encouraging. A solid international foothold and a strong product portfolio bode well. Strong solvency is an added advantage.

DexCom’s FDA-cleared CGM system – the DexCom G4 Platinum has been boosting its top line. The inbuilt features of the G4 Platinum make it the most innovative system for continuous glucose monitoring in the market. In July 2021, DexCom announced the FDA’s clearance for Dexcom Partner Web APIs. The latest nod will enable approved third-party developers to integrate real-time CGM data into their digital health apps and devices.

This Zacks Rank #2 company has an Earnings ESP of +5.46{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. The Zacks Consensus Estimate for current-year earnings improved 0.4{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} over the last 30 days. It recorded earnings surprises in the last four reported quarters, with an average beat of 32.5{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. The company is set to release earnings results on Oct 28, after the closing bell.

Exxon Mobil made multiple world-class oil discoveries at the Stabroek Block, located off the coast of Guyana. Recently, the company raised the estimate for discovered recoverable resources from the Stabroek Block to approximately 10 billion oil-equivalent barrels.

Its bellwether status and an optimal integrated capital structure that has historically produced industry-leading returns make it a relatively lower-risk energy sector play. The integrated oil behemoth expects to reduce greenhouse gas emissions by 30{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in its upstream business. During the same time frame, the firm expects to reduce flaring and methane emissions by 40{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}.

This Zacks Rank #1 company has an Earnings ESP of +1.57{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. The company has an expected earnings growth rate of more than 100{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} for the current year. The Zacks Consensus Estimate for current-year earnings improved 2{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} over the last 7 days. The company is set to release earnings results on Oct 29, before the opening bell.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                      

https://www.zacks.com                                          

 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Exxon Mobil Corporation (XOM) : Free Stock Analysis Report
 
Capital One Financial Corporation (COF) : Free Stock Analysis Report
 
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
 
Aflac Incorporated (AFL) : Free Stock Analysis Report
 
DexCom, Inc. (DXCM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.